Apr. 24 at 1:27 PM
$VIR
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Updater
NOTE: Full review over at TipRanks
Vir Biotechnology, Inc. VIR announced an update on their ongoing clinical study.
The phase 2 study “A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection” aims to test new drug combinations for long-term control of chronic hepatitis B. It focuses on safety, how well patients tolerate treatment, and early signs that these drugs could move the market toward more functional cures.
The study tests three injected drugs: VIR-2218 (elebsiran), VIR-3434 (tobevibart), and PEG-IFNα. They are designed to work together to lower virus levels and boost the immune response, with the goal of reducing or replacing long-term daily oral therapy.
